Next Article in Journal
Study of the Association between Thiols and Oxidative Stress Markers in Children with Obesity
Next Article in Special Issue
The Role of D-Serine and D-Aspartate in the Pathogenesis and Therapy of Treatment-Resistant Schizophrenia
Previous Article in Journal
Reconfiguration of Gut Microbiota and Reprogramming of Liver Metabolism with Phycobiliproteins Bioactive Peptides to Rehabilitate Obese Rats
Previous Article in Special Issue
Pretreatment Glasgow Prognostic Score Correlated with Serum Histidine Level and Three-Year Mortality of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma and Optimal Performance Status
 
 
Brief Report
Peer-Review Record

Nutritional Niches of Cancer Therapy-Induced Senescent Cells

Nutrients 2022, 14(17), 3636; https://doi.org/10.3390/nu14173636
by Àngela Llop-Hernández 1, Sara Verdura 2, Elisabet Cuyàs 1,2,* and Javier A. Menendez 1,2,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Nutrients 2022, 14(17), 3636; https://doi.org/10.3390/nu14173636
Submission received: 5 August 2022 / Revised: 30 August 2022 / Accepted: 31 August 2022 / Published: 2 September 2022
(This article belongs to the Special Issue Amino Acid Metabolism in Human Health and Disease)

Round 1

Reviewer 1 Report

 

 Therapy-induced senescence (TIS) is a state of stable proliferative arrest of both normal and neoplastic cells that is triggered by exposure to anticancer treatments. TIS cells acquire a senes-cence-associated secretory phenotype (SASP), which is proinflammatory and actively promotes tumor relapse and adverse sideeffects in patients. 

--Comment: Appropriately explained in Intro.

 

The authors hypothesized that TIS cells adapt their scavenging and/or catabolic ability to overcome the nutritional constraints in their microenvironmental niches. They used a panel of mechanistically-diverse TIS triggers and Biolog Phenotype MicroArrays to identify (among 190 different carbon and nitrogen sources) candidate metabolites that support the survival of TIS cells in limiting nutrient conditions. 

 

--Comment: Here the raw data are missing and a full list of the 190 carbon and nitrogen sources. If you think you have included this already, please stress this a bit more in the results section. Furthermore, provide a supplement with the full original data. Do also statistics, what are significant measurements etc.

 

We provide evidence of distinguishable TIS-associated nutrient consumption profiles involving a core set of shared (e.g., glutamine) and more unique (e.g., glucose-1-phosphate, inosine and uridine) nutritional sources after diverse senescence-inducing interventions. We also observed a trend for an inverse correlation between the intensity of the pro-inflammatory SASP provoked by different TIS agents and the diversity of compensatory nutritional niches utilizable by senescent cells. These findings support the detailed exploration of the nutritional niche as a new metabolic dimension to understand and target TIS in cancer. 

 

--Comment: Is reasonable well done, however, discussion should stress a bit more earlier findings and publications supporting these observations.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

The authors hypothesized that TIS cells adapt their scavenging and/or catabolic ability to overcome the nutritional constraints in their microenvironmental niches. They used a panel of mechanistically-diverse TIS triggers and Biolog Phenotype MicroArrays to identify (among 190 different carbon and nitrogen sources) candidate metabolites that support the survival of TIS cells in limiting nutrient conditions.

Moreover, the authors showed for the first time that utilization patterns of different carbon/nitrogen energy sources under compromised nutritional conditions vary across different types of TIS cells, which would likely make them differentially responsive to changes in their nutritional microenvironment. The research work is very innovative and interesting with a great impact on practical applications. So, the manuscript is presented very well and I propose only minor revisions:

        1) To a better evaluation of results due to the proliferation after some treatments and/or co-transfection, it can be useful to report also the evaluation of a proliferation assay (as MTT or equivalent assay) and/or cytotoxicity assay (as lactate dehydrogenase) as control.

        2) It need to insert the numbers of Figure captures under each figure

    3) It need to substitute in text (Fig. 5) with (Figure 5) for the whole uniformity of the paper, and to correct β-galactosidase in figure capture of Fig 5, instead of @-galactosidase.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop